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Figure 1 Spline curve of the association between endostatin and the composite outcome in the discovery and replication sample (panel A 
and B, respectively) 
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Abstract 
Background and aim: Raised levels of serum endostatin, a biologically active fragment of 
collagen XVIII, have been observed in patients with ischemic heart disease but associations with 
incident cardiovascular events in patients with stable coronary heart disease is uncertain. 
Methods: The CLARICOR-trial is a randomised, placebo-controlled trial of stable coronary heart 
disease patients evaluating 14-day treatment with clarithromycin. The primary outcome was a 
composite of acute myocardial infarction, unstable angina pectoris, cerebrovascular disease or all-
cause mortality. In the present sub-study using 10-year follow-up data, we investigated associations 
between serum endostatin at entry (randomization) and the composite outcome and its components 
during follow-up. The placebo group was used as a discovery sample (1204 events, n=1998) and the 
clarithromycin-treated group as replication sample (1220 events, n=1979).  
Results: In Cox regression models adjusting for cardiovascular risk factors, glomerular filtration 
rate, and current pharmacological treatment, higher serum endostatin was associated with an 
increased risk of the composite outcome in the discovery sample (hazard ratio per standard 
deviation increase 1.11, 95% CI 1.03-1.19, p=0.004), but slightly weaker and not statistically 
significant in the replication sample (hazard ratio 1.06, 95 % CI 1.00-1.14, p=0.06). In contrast, 
strong and consistent associations were found between endostatin and cardiovascular and all-cause 
mortality in all multivariable models and sub-samples. Addition of endostatin to a model with 
established cardiovascular risk factors provided no substantial improvement of risk prediction 
(<1%).  
Conclusion:  Raised levels of serum endostatin might be associated with cardiovascular events in 
patients with stable coronary heart disease. The clinical utility of endostatin measurements remains 
to be established. 
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Abbreviations 
CLARICOR:  effect of clarithromycin versus placebo on mortality and morbidity in patients with 
ischemic heart disease 
 
 
Introduction 
Collagen XVIII, a major component of the basal membranes, is a heparin sulphate proteoglycan 
with multifunctional activity. Cleavage of collagen XVIII during extracellular matrix (ECM) 
remodelling gives rise to endostatin, a biologically active fragment with anti-angiogenic and anti-
fibrotic activity 1-3. Endostatin has been thoroughly studied in the field of malignant diseases, and 
has been suggested to reflect extracellular matrix turnover during tumour growth 4.   
Apart from its role in cancer growth, endostatin has been shown to contribute to atherosclerosis, and 
raised levels of serum endostatin are associated with the risk of various cardiovascular diseases 5-10 
as well as with cardiovascular mortality 11. Despite the importance of endostatin in the development 
of cardiovascular disease, few studies have evaluated serum endostatin as a biomarker for coronary 
heart disease and cardiovascular prognosis, particularly few in patients with prevalent 
cardiovascular disease.   
Here, we aimed to assess the association between serum endostatin and future risk of adverse 
cardiovascular events in persons with stable coronary heart disease at baseline. We hypothesized 
that elevated levels of serum endostatin reflect cardiovascular damage that predisposes to a 
cardiovascular event. 
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Methods 
Study design and patients 
In 1999, all residents of Copenhagen, Denmark, with a hospital diagnosis of myocardial infarction 
or angina pectoris (International Statistical Classification of Diseases (ICD) codes I20.9-I21.9) 
between 1993-1999 were invited to participate in the randomized, placebo-controlled, multi-centre 
CLARICOR (effect of clarithromycin versus placebo on mortality and morbidity in patients with 
ischemic heart disease) trial. After providing informed consent, eligible participants with stable 
coronary heart disease (excluding persons who had suffered from acute myocardial infarction or 
unstable angina pectoris episode during the previous 3 months and those that had been subjected to 
percutaneous transluminal coronary angioplasty and coronary bypass surgery during the last 6 
months) were randomly assigned to 14-days of treatment with either oral clarithromycin 500 mg 
once daily (Klacid Uno®, Abbott, UK) or placebo. Other exclusion criteria included New York 
Heart Association class IV heart failure, impaired renal or hepatic function, or cancer. In total, 
4,372 patients with stable coronary heart disease were randomized, 4,350 patients donated blood 
and serum samples were available for analysis in 4,298 patients. Participants were followed for a 
maximum of ten years from the end of treatment in April 2000 until 31st of December 2009. The 
results on the effects of clarithromycin on cardiovascular outcomes and mortality as well as on 
adverse events have previously been reported 12-18. In the present sub-study of CLARICOR, we 
used the placebo arm as a discovery sample for the investigating the association between serum 
endostatin and outcome, and the clarithromycin arm as a replication sample. We excluded 
participants with missing data in any of the variables, leaving n=1,998 participants in the discovery 
sample, and n=1,979 in the replication sample. 
Outcomes 
Outcome information about fatal and non-fatal hospital episodes were extracted from the Danish 
National Hospital Register that records hospital admissions for all registered Danish residents via 
linkage to the 10-digit central person registration number. Information about dates and causes of 
death were obtained from the Danish Central Civil Register and the National Register of Causes of 
Death. For each recorded main diagnosis and for each underlying cause of death, we classified the 
outcomes into: acute myocardial infarction (ICD codes I21.0–23.9); unstable angina pectoris (I20.0, 
I24.8–24.9); cerebrovascular disease (I60.0–64.9 and G45.0–46.8); peripheral vascular disease 
(I70.2–70.9); other cardiovascular diseases (I00.0–99.9 unless already covered); and non-
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cardiovascular disease (A00.0-T98.3 unless already covered) 16. The a-priori defined composite 
outcome comprised of acute myocardial infarction, unstable angina pectoris, cerebrovascular 
disease, or all-cause death during follow-up.  
 
Laboratory analyses 
Laboratory analyses were performed on Mindray BS380 (Mindray, Shenzhen, China) with reagents 
from Abbott Laboratories (Abbott Park, IL, USA) according to the manufacturer's instructions 
(Supplementary table 1). Estimated glomerular filtration rate (eGFR) was estimated using the 
creatinine based CKD-EPI formula 19 Blood samples were obtained at entry (randomization), prior 
to the initiation of treatment, and immediately frozen and stored at  -70˚ C or lower. Serum levels of 
endostatin were analysed using a commercially available ELISA kit for endostatin (DY1098, R&D 
Systems, Minneapolis, MN). The assays had a total coefficient of variation (CV) of approximately 
7%. Laboratory technicians were blinded to participant assignment. 
 
Ethics 
CLARICOR complies with the Declaration of Helsinki and has been approved by the local ethics 
committees (ClinicalTrials.gov NCT00121550; Regional Ethics Committee KF 01-076/99 and HB 
2009/015; the Danish Data Protection Agency 1999-1200-174 and 2012-41-0757; and the Danish 
Medicines Agency 2612–975). All participants gave written informed consent. 
 
Statistical analyses 
For all analyses, endostatin serum levels were natural logarithm-transformed in order to promote a 
normal distribution and expressed per standard deviation increase. Log-transformation was also 
applied to CRP and apolipoprotein B. The following adjusted Cox proportional hazards regression 
models were used to assessed the association between endostatin and outcomes:  
 Model A was adjusted for age, sex, and CRP. Model B was adjusted for factors in model A and 
established cardiovascular risk factors (hypertension, diabetes, smoking, apolipoprotein A1, and 
apolipoprotein B). Model C was adjusted for factors in model B and eGFR. Model D was adjusted 
for established risk factors, co-morbidities and cardiovascular pharmacotherapies, and standard 
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biochemical predictors as shown in Table 1. Model D was considered the primary model in 
accordance with the pre-specified analyses plan 20.  
 
We used penalized spline curves to depict the potential nonlinearity of the association between 
endostatin and the composite outcome.   
For the composite outcome and for all-cause mortality, the proportional hazards assumption was 
violated for age at entry (Bonferroni adjusted p < 0.00056 for the composite outcome, and p < 
0.0044 for all-cause mortality). Therefore, we excluded age from all multivariable models for those 
two outcomes. In order to provide additional insights into the potential influence of age on these 
associations we conducted multivariable logistic regression models (including age as a covariate as 
the proportional hazard assumption are not a prerequisite for these analyses).  
 
In accordance with the published statistical analysis plan 20, improvement in risk prediction when 
adding endostatin to multivariable Model D was calculated (please see as explained in note to 
table).  
 
Analyses were conducted in STATA, version 14.2 (College Station, Texas, USA) and SAS 9.4 
(SAS Institute, Inc.100 SAS Campus Drive, Cary, NC 27513-2414). 
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Results 
The baseline demographic data of the discovery and replication cohorts are described in Table 2. 
There were no obvious differences in these variables between the two samples. 
The mean follow-up was 6.5 years in the discovery and 6.4 years in the replication cohort sample; 
maximum follow-up was 10.2 years in both samples. Table 3 shows the number of events and 
incidence rates per 100 person-years for the primary composite outcome and the secondary 
outcomes. The two groups have very similar rates (p > 0.60 in all rows).  
The crude association between serum endostatin and the composite outcome in the discovery and 
replication sample is graphically depicted by spline curves in Figure 1. Visual examination of the 
curves suggests a linear increase in hazard for higher endostatin levels in both samples. 
As seen in Table 4, higher serum endostatin was associated with an increased risk of the composite 
outcome in the both the discovery and replication sample in models adjusted for sex, CRP, 
established cardiovascular risk factors, and eGFR (Models A-C). In the fully-adjusted model (model 
D) endostatin levels were not quite so strongly associated with the composite outcome, reaching 
significance in the discovery cohort only (hazard ratio per standard deviation increase of endostatin 
1.11, 95 % CI 1.03 – 1.19, p=0.004) vs. replication HR = 1.06, 95 % CI 1.00 – 1.14, p=0.064). 
However, in the multivariable logistic regression analyses that also included age as a co-variate, 
higher endostatin was associated with an increased risk of the composite outcome in both the 
discovery and replication sample (Model D, Supplementary table 2).   
As regards the secondary Cox analyses in Table 4, one observes that myocardial infarction closely 
follows the hazard ratio pattern just described for the composite outcome. Cardiovascular as well as 
total mortality was more strongly associated with higher endostatin levels in all multivariable 
models in both cohorts, whereas the outcomes stroke, unstable angina show no consistent 
association with endostatin.  
Prediction improvement 
The number and percent of correct predictions obtained for the composite outcome and all-cause 
mortality when endostatin was added to standard predictors are shown in Table 5. Only small 
improvements were seen (<1%). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
Discussion 
Main findings 
In a large study of patients with stable coronary heart disease, higher levels of serum endostatin 
might be related with an increased 10-year risk of cardiovascular events in patients with stable 
coronary heart disease. These associations were found in both the discovery and replication sample 
of the study, with statistically compatible hazard ratios, although the replication data were also 
formally compatible with there being no association when examined under the conditions of the 
pre-defined fully adjusted model (p=0.06). The strongest associations, however, were seen between 
higher serum endostatin and cardiovascular and all-cause mortality.  
 
Strengths and limitations  
Major strengths of the present study include the discovery replication approach in a large study 
sample with detailed characterization of the participants, and the longitudinal study design with up 
to 10 years of follow-up. The present cohort study is to our knowledge the largest study that has 
measured circulating levels of endostatin, and the first in patients with stable coronary heart disease.  
Moreover, the National Danish Registers are known to be of high completeness and accuracy 17. 
Limitations include the unknown generalizability to other ethnic groups. In addition, diabetes and 
hypertension were only self-reported which may have led to an increased misclassification of these 
cardiovascular risk factors. As we have no repeated blood sampling for endostatin analyses, it was 
not possible to evaluate the effects of clarithromycin treatment on circulating endostatin levels. 
 
 
Comparison with previous studies 
In two previous studies, serum endostatin was increased in patients with acute myocardial 
infarction21, 22. Also, higher serum endostatin in the coronary circulation of patients with ischemic 
heart disease were associated with poorer collateral formation 23 and expression of endostatin is 
increased in human heart biopsies from patients with non-ST elevation myocardial infarction 22. 
Moreover, our results are in accordance with a previous community-based study, in which 
associations between endostatin and cardiovascular death were particularly strong in individuals 
with a history of cardiovascular disease compared to those without 11. Still, to our knowledge, this 
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study is the first to report the association between circulating endostatin and adverse cardiovascular 
outcomes in patients with stable coronary heart disease.  
 
 
Possible mechanisms for observed associations 
One interpretation of the association between higher serum endostatin levels and cardiovascular 
events, could be that higher circulating levels of endostatin in patients with stable ischemic heart 
disease mirror an increased systemic active extracellular matrix re-modulation driven by an 
increased inflammatory stress (inflammatory cytokines, hypoxia, ischemia) as seen in patient with 
atherosclerosis and cardiovascular diseases 24. Specifically, this state of increased inflammation will 
stimulate elastase, matrix-derived metalloproteinases (MMP), as well as the cathepsins, all known 
to be involved in the release of endostatin from the basal membrane 1, 3, 25, 26. Additionally, 
inflammation may not only initiate the reactions leading to extracellular matrix remodelling and 
atherosclerotic lesions; but may also trigger plaque rupture, the final event behind most thrombotic 
and atherosclerotic manifestations events24.  
It is also possible that the association between endostatin and cardiovascular mortality reflects 
systemically increased angiogenic activity initiated by an angiogenic stimulus involving 
extracellular matrix remodelling and release of endostatin. Vascular endothelial growth factor 
(VEGF), one of the most potent endogenous stimulators of angiogenesis, is regulated by hypoxia, 
inflammatory cytokines as well as oncogenes 27, 28. Initiation of angiogenesis by VEGF involves 
extracellular matrix degradation and leads to an imbalance in the local angiogenic milieu favouring 
angiogenesis. As a consequence to the extracellular matrix breakdown, endostatin is released in 
order to maintain homeostasis in the angiogenic milieu. Alteration in the systemic balance of pro 
and anti-angiogenic homeostasis has been shown to be a key factor in the destabilization of 
atherosclerotic plaques 29.  
ECM remodelling as observed in ischemic heart disease leads to substantial pathological deposition 
of extracellular matrix proteins in the myocardium and cardiac fibrosis 24, 30. The extracellular 
matrix remodelling process can be initiated for example by hypertension, cardiac stress, valve 
dysfunction, hypertrophy of the myocardium and by myocardial infarction 30. Cardiac fibrosis has 
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been suggested to be associated with a reduction in local capillary perfusion leading to tissue 
hypoxia and a subsequent activation of the angiogenic milieu 31. It has been shown that the 
expression of endostatin is increased in rat cardiomyocytes exposed to hypoxia as well as after 
induction of a myocardial infarction 32. Moreover, an association between endostatin and reduced 
collateral circulation has been shown repeatedly in previous studies 7, 23, 33. Thus, there is evidence 
that local cardiac fibrosis and hypoxia following atherosclerotic changes in the coronary circulation 
may promote an increased expression of endostatin, which can lead to a subsequent systemic 
increase of circulating endostatin.  
Also, endostatin has been put forward as a relevant marker for kidney damage and dysfunction in 
patients with diabetes 34, and in the general population  35. Moreover, endostatin levels have been 
shown to be associated with underlying factors that predispose to both chronic kidney disease and 
ischemic heart disease such as diabetes 33, 36, 37 and the duration of hypertension 5. Therefore, it is 
possible that individuals with elevated circulating endostatin are more likely to develop chronic 
kidney disease, which in turn substantially increases the risk of cardiovascular events. However, the 
associations remained robust after adjustment for baseline eGFR, indicating that other pathways are 
important as well. 
 
Clinical implications 
With the development of novel (and costly) treatment regimens such as proprotein-convertase 
subtilisin kexin type 9 (PCSK9) inhibitors 39 or canakinumab, that target the interleukin-1β innate 
immunity pathway 40 an improved identification of high risk patients with prevalent cardiovascular 
disease that would benefit of such treatments will be increasingly important. Even though 
endostatin predicted adverse cardiovascular events in the present study, the improvement in risk 
prediction was low and our data do not support a clinical utility for endostatin measurements in 
patients with stable coronary heart disease.  
Conclusions 
Raised levels of serum endostatin might be associated with cardiovascular events in patients with 
stable coronary heart disease. Yet, the clinical utility of our findings remains to be established.  
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Table 1.  Standard predictors adjusted for in Model D 
 
Clinical predictors Current medical treatment Standard biochemical predictors 
Sex, age, smoking history, 
history of myocardial infarction 
compared to angina only, 
hypertension, 
and diabetes. 
 
The current 
medical treatment was included 
as proxy predictors because 
information about post infarction 
heart failure and post-infarction 
angina pectoris are not available 
to us. 
Aspirin (Yes/No), beta-blocker 
(Yes/No), calcium-antagonist 
(Yes/No), ACE-inhibitor (Yes/ 
No), long lasting nitrate 
(Yes/No), diuretic (Yes/No), 
digoxin (Yes/No), statin 
(Yes/No), and anti-arrhythmic 
drugs (Yes/No).  
 
 
Log transformed high-sensitivity-
reactive protein (CRP), 
glomerular filtration rate (GFR) 
estimated by creatinine, 
triglycerides and 
lipoproteins (total cholesterol, 
HDL cholesterol, LDL 
cholesterol, apoprotein A1, and 
apoprotein B). 
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Table 2 Baseline characteristics in the discovery (placebo) and replication (clarithromycin) cohorts 
 
Variable Discovery 
cohort 
Replication 
cohort 
Number of participants 1998 1979 
Female   624 (31) 603 (30) 
Age (years) 65 ±10 65 ±10 
Endostatin (ng/ml)  31.4 ±1.2 32.0 ±1.2  
CRP (mg/L) 5.25 ±7.7 5.76 ±9.3 
Apolipoprotein A1 (mg/dL) 1.70 ±0.34 1.70 ±0.36 
Apolipoprotein B (mg/dL) 1.21 ±0.32 1.21 ±0.33 
Diabetes  300 (15) 301 (15) 
Hypertension 805 (40) 790 (40) 
eGFR (ml/min) 76.3 ±20 76.5 ±19 
Never smoked 395 (20) 338 (17) 
Former smoker 925 (46) 906 (46) 
Current smoker 678 (34) 735 (37) 
Previous myocardial infarction 636 (32) 640 (32) 
Statin treatment 822 (41) 814 (41) 
Aspirin treatment  1764 (88) 1737 (88) 
Beta blocker treatment  619 (31) 591 (30) 
Calcium antagonist treatment  702 (35) 681 (34) 
ACE inhibitor treatment  523 (26) 553 (28) 
Long acting nitrate treatment  412 (21) 411 (21) 
Diuretics  691 (37) 702 (35) 
Digoxine treatment  117 (7) 140 (7) 
Antiarrhythmic treatment 42 (2) 46 (2) 
Data are mean ± standard deviation for continuous variables and n (%) for categorical variables 
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Table 3. Number of events and incidence rates with 95% confidence intervals  
Outcomes  Discovery cohort Replication cohort 
Composite 
outcome 
NE (%) 
IR per 100 years 
95% CI 
1204 (60) 
9.23 
8.72 - 9.76 
1220 (62) 
9.67 
9.15 - 10.23 
Acute 
myocardial 
infarction 
NE (%) 
IR per 100 years 
95% CI 
446 (22) 
2.97  
2.71 – 3.26 
422 (21) 
2.90 
2.63 – 3.19 
Unstable 
angina 
pectoris 
NE (%) 
IR per 100 years 
95% CI 
356 (18) 
2.40 
2.16-2.66 
356 (18) 
2.50 
2.25 – 2.77 
Stroke NE (%) 
IR per 100 years 
95% CI 
298 (15) 
1.91 
1.71 – 2.14 
324 (16) 
2.18 
1.96 – 2.43 
Cardiovascul
ar mortality 
NE (%) 
IR per 100 years 
95% CI 
382 (19) 
2.39 
2.15 – 2.64 
348 (17) 
2.10 
1.88 – 2.32 
Non-
cardiovascula
r mortality 
NE (%) 
IR per 100 years 
95% CI 
390 
2.34  
2.12 – 2.59 
406 
2.54 
2.30 – 2.80 
All-cause 
mortality 
NE (%) 
IR per 100 years 
95% CI 
738 (37) 
4.44 
4.13 – 4.77 
788 (40) 
4.92 
4.59 – 5.28 
NE= Number of events (% of participants at risk). IR= incidence rate: Number of events per 100 person years follow-
up, lower/upper bounds of 95% confidence intervals.  
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Table 4. The association between serum endostatin and endpoints in Cox regression models; hazard ratios are per 1SD increment.  
 
  Discovery cohort Replication cohort 
  Model A Model B Model C Model D Model A Model B Model C Model D 
Composite 
outcome* 
Hazard ratio 
95% CI 
p-value 
1.30 
1.23-1.38 
<0.001 
1.31 
1.23-1.39 
<0.001 
1.14 
1.06-1.21 
<0.001 
1.11 
1.03-1.19 
0.004 
1.27 
1.20-1.35 
<0.001 
1.26 
1.19-1.34 
<0.001 
1.10 
1.03-1.17 
0.004 
1.06 
1.00-1.14 
0.064 
Acute 
myocardial 
infarction 
Hazard ratio 
95% CI 
p-value 
1.29 
1.17-1.42 
<0.001 
1.26 
1.14-1.39 
<0.001 
1.19 
1.07-1.33 
0.002 
1.19 
1.06-1.33 
0.004 
1.18 
1.07-1.30 
0.001 
1.16 
1.05-1.28 
0.003 
1.12 
1.00-1.25 
0.050 
1.07 
0.96-1.20 
0.22 
Unstable 
angina pectoris 
Hazard ratio 
95% CI 
p-value 
1.13 
1.01-1.26 
0.032 
1.14 
1.02-1.27 
0.024 
1.14 
1.00-1.29 
0.045 
1.06 
0.93-1.20 
0.39 
1.10 
0.99-1.23 
0.077 
1.10 
0.98-1.22 
0.097 
1.09 
0.97-1.24 
0.16 
1.08 
0.96-1.23 
0.20 
Stroke Hazard ratio 
95% CI 
p-value 
1.06 
0.94-1.20 
0.34 
1.04 
0.92-1.18 
0.52 
1.00 
0.88-1.15 
0.95 
0.97 
0.84-1.11 
0.63 
1.05 
0.94-1.18 
0.38 
1.02 
0.91-1.15 
0.14 
0.97 
0.85-1.10 
0.62 
0.93 
0.82-1.07 
0.31 
Cardiovascular 
mortality 
Hazard ratio 
95% CI 
p-value 
1.46 
1.31-1.63 
<0.001 
1.48 
1.33-1.65 
<0.001 
1.39 
1.23-1.58 
<0.001 
1.33 
1.17 – 1.52 
<0.001 
1.38 
1.24-1.52 
<0.001 
1.33 
1.20 – 1.47 
<0.001 
1.25 
1.11 – 1.41 
<0.001 
1.14 
1.01 – 1.30 
0.030 
Non-
cardiovascular 
mortality 
Hazard ratio 
95% CI 
p-value 
1.17 
1.06-1.30 
<0.001 
1.22 
1.10-1.36 
<0.001 
1.14 
1.01-1.28 
<0.036 
1.11 
0.98-1.26 
0.086 
1.30 
1.17-1.43 
<0.001 
 
1.31 
1.19-1.45 
<0.001 
1.23 
1.10-1.38 
<0.001 
1.21 
1.07-1.36 
0.002 
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All-cause 
mortality* 
Hazard ratio 
95% CI 
p-value 
1.54 
1.43-1.65 
<0.001 
1.57 
1.46-1.69 
<0.001 
 
1.20 
1.10-1.31 
<0.001 
1.18 
1.08-1.28 
<0.001 
1.47 
1.37-1.58 
<0.001 
1.46 
1.36-1.56 
<0.001 
1.15 
1.06-1.24 
0.001 
1.09 
1.00-1.18 
<0.05 
CI confidence interval. Model A was adjusted for age, sex and C-reactive protein. Model B was adjusted for factors in model A and established cardiovascular risk factors (hypertension, 
diabetes, smoking, apolipoprotein a1, and apolipoprotein B). Model C was adjusted for factors in model B and estimated glomerular filtration rate (eGFR). Model D was adjusted for 
established risk factors and co-morbidities, standard biochemical predictors and treatments as shown in Supplementary Table 1.  
* Proportional hazards assumption was violated for age; all models in this row is shown without adjustments for age.  
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Table 5. Improvement of outcome prediction by adding endostatin to the standard predictor full model 
 
 
 
 
 
 
 
 
 
 
 
 
*A favorable (or unfavorable) prediction assigns > 50% (< 50%) probability to being alive on a given day; the prediction is ‘true’ when the patient was 
in fact alive (or no longer alive). Three timepoints were examined, viz. the participant’s 3, 6 and 9-year date after randomization. Thus, the total number 
of predictions is 3*number of participants minus losses to follow-up. – We show the increase in the number of true predictions when we use endostatin 
plus the standard predictors instead of using only the standard predictors for the outcome all-cause mortality. This amounts to 4993 – 4977 = 16. In 
percent of the total number of predictions made at the three time points (5971) this amounts to 16/5971 (0.27%). 
Type of predictions The composite outcome 
Standard predictors 
included (SP) 
SP plus 
Biomarker 
included 
Total 
predictions* 
True favorable predictions N (%)* 2910 (48.7) 2927(49.0)  
True unfavorable predictions N 
(%) 
1174 (19.7) 1169(19.6)  
Total number of true predictions N 
(%) 
4084 (68.4) 4096(68.6) 5972 
 
True favorable predictions N (%) 
All-cause mortality 
4585 (76.8) 4592(76.9)  
True unfavorable predictions N 
(%) 
392(6.57) 401 (6.72)  
Total number of true predictions N 
(%) 
4977 (83.4) 4993 (83.6) 5971 
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Figure 1 Spline curve of the association between endostatin and the composite outcome in the discovery and replication sample (panel A 
and B, respectively) 
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Highlights 
 
• In Cox regression models adjusting for cardiovascular risk factors, glomerular 
filtration rate, and current pharmacological treatment, higher serum endostatin was 
associated with an increased risk of the composite outcome (acute myocardial 
infarction, unstable angina pectoris, cerebrovascular disease or all-cause mortality) in 
the discovery sample but not in the replication sample. 
• Strong and consistent associations were found between endostatin and cardiovascular 
and all-cause mortality in all multivariable models and sub-samples. 
• We believe that these results imply that endostatin might be involved in the 
development of cardiovascular events in patients with stable coronary heart disease. 
 
